サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1777783

解毒剤の世界市場

Antidotes

出版日
ページ情報
英文 381 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.64円
解毒剤の世界市場
出版日: 2025年07月28日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 381 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

解毒剤の世界市場は2030年までに33億米ドルに到達

2024年に23億米ドルと推定される解毒剤の世界市場は、2024年から2030年にかけてCAGR 6.6%で成長し、2030年には33億米ドルに達すると予測されます。本レポートで分析したセグメントの一つである化学的解毒剤は、CAGR7.4％を記録し、分析期間終了時には18億米ドルに達すると予測されます。薬理学的解毒剤セグメントの成長率は、分析期間でCAGR 5.8％と推定されます。

米国市場は6億1,440万米ドルと推定、中国はCAGR10.4％で成長予測

米国の解毒剤市場は、2024年に6億1,440万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを10.4%として、2030年までに6億8,730万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.2%と6.4%と予測されています。欧州では、ドイツがCAGR 4.3%で成長すると予測されています。

世界の解毒剤市場- 主要動向と促進要因のまとめ

解毒剤の需要が複数のセクターで急増している理由とは？解毒剤の需要は、様々な産業における中毒、薬物の過剰摂取、有害物質への暴露事例の増加により、増加傾向にあります。職場や家庭におけるオピオイドの過剰摂取、偶発的な中毒、化学物質への暴露の増加により、効果的な解毒剤の普及が必要とされています。オピオイド危機は、特に北米と欧州の一部で、ナロキソンのようなオピオイド逆転薬の需要を著しく高めています。さらに、農業や産業環境における農薬や化学物質関連の中毒事故の急増により、ヘルスケアプロバイダーや規制機関は、必要不可欠な解毒剤の備蓄と配布を優先するようになりました。公衆衛生上の危機が世界的に拡大する中、複雑化する中毒症例に対応するため、解毒剤の開発は進化し続けています。

規制と安全プロトコルは市場力学をどのように形成しているか？解毒剤市場は高度に規制された枠組みの中で運営されており、政府機関やヘルスケア機関は安全性と有効性に関する厳しい要件を課しています。解毒剤の承認プロセスは厳格で、緊急時のシナリオにおける有効性を確保するために、大規模な臨床試験と実地試験が必要とされます。FDA、EMA、WHOなどの規制機関の役割は、救命用解毒剤の承認を合理化し、病院、薬局、緊急対応ユニットでの利用可能性を確保する上で極めて重要となっています。さらに、有毒物質への曝露による死亡率を減少させようという世界の動向から、国家備蓄プログラムへの投資も増加しています。多くの政府や国際保健機関は、解毒剤の製造と配布を公衆衛生政策の重要な要素として優先しており、中毒事故やバイオハザード緊急事態への迅速な対応を確保しています。市場はまた、プレフィルド自動注射器や経鼻投与メカニズムへのシフトを目の当たりにしており、一刻を争う症例におけるアクセスのしやすさと投与のしやすさを向上させています。

解毒剤の有効性を変える最先端の技術革新とは？医薬品と生物医学研究の技術的進歩は、解毒剤の製剤に革命をもたらし、より効果的で、即効性があり、投与が容易になっています。モノクローナル抗体をベースとした解毒剤や標的酵素阻害剤のような技術革新は、特定の毒性曝露に対する治療の特異性を向上させています。並行して、ドラッグデリバリーにおけるナノテクノロジーの統合は、解毒剤のバイオアベイラビリティを向上させ、体内での毒素の徐放性とより正確なターゲティングを可能にしています。さらに、AIを活用した創薬により、膨大な化学データベースを解析して毒物学的プロファイルを潜在的な解毒剤と照合することで、新規解毒化合物の同定が加速しています。オピオイド過剰摂取やシアン化物中毒に対する単回投与自動注射器などのポイント・オブ・ケア型解毒剤ソリューションの採用は、病院ベースの治療への依存を減らし、危機的なシナリオにおける即時介入を容易にしています。こうした最先端の開発により、解毒剤治療は、携帯性と迅速な投与が重視され、より患者中心のものとなりつつあります。

市場拡大を促進する主な成長要因は何か？世界の解毒剤市場の成長は、薬物の過剰摂取や産業化学物質への暴露の増加、緊急事態への備えに対する世界の関心の高まりなど、いくつかの要因によってもたらされています。タイムリーな介入の重要性に対するヘルスケア専門家や一般市民の意識の高まりは、病院、救急車、さらには家庭における解毒剤の備蓄の増加につながっています。さらに、拡大する製薬業界は、蛇咬傷、重金属中毒、バイオテロ関連の毒性物質に対する解毒剤を含む、新規の解毒療法の開発を促進しています。病院前の救急医療に対する需要の高まりは、携帯型解毒製剤の開発とともに市場の成長をさらに促進しています。さらに、毒物学研究のための政府資金の増加は、バイオテクノロジー企業と公衆衛生機関の間の戦略的パートナーシップと相まって、先進的な解毒剤ソリューションの安定したパイプラインを確保しています。このような市場促進要因の積み重ねが、進化し続ける毒物学的脅威に対応し、解毒剤の入手しやすさと効率性の未来を形成しています。

セグメント

タイプ（化学的解毒剤、薬理学的解毒剤、物理的解毒剤）、投与ルート（注射ルート、経口ルート、その他の投与ルート）、エンドユーザー（病院エンドユーザー、専門クリニックエンドユーザー、その他のエンドユーザー）

調査対象企業の例

  • Acrotech Biopharma, Inc.
  • American Regent, Inc.
  • Baxter International, Inc.
  • Cumberland Pharmaceuticals, Inc.
  • Emergent BioSolutions, Inc.
  • Global Calcium Private Limited
  • Heyl Chemisch-pharmazeutische Fabrik GmbH & Company KG
  • Indivior Plc
  • Padagis US, LLC
  • Pfizer, Inc.
  • ZIMHI
  • Zydus Pharmaceuticals（USA）Inc.

AI統合

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP29184

Global Antidotes Market to Reach US$3.3 Billion by 2030

The global market for Antidotes estimated at US$2.3 Billion in the year 2024, is expected to reach US$3.3 Billion by 2030, growing at a CAGR of 6.6% over the analysis period 2024-2030. Chemical Antidote, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the Pharmacological Antidote segment is estimated at 5.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$614.4 Million While China is Forecast to Grow at 10.4% CAGR

The Antidotes market in the U.S. is estimated at US$614.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$687.3 Million by the year 2030 trailing a CAGR of 10.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.2% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.

Global Antidotes Market - Key Trends & Drivers Summarized

Why Is the Demand for Antidotes Surging Across Multiple Sectors? The demand for antidotes has been on an upward trajectory, driven by rising cases of poisoning, drug overdoses, and exposure to toxic substances in various industries. The increasing prevalence of opioid overdoses, accidental poisoning, and chemical exposure in workplaces and households has necessitated the widespread availability of effective antidotes. The opioid crisis, particularly in North America and parts of Europe, has significantly heightened the demand for opioid reversal drugs like naloxone, which is now being made available in over-the-counter formulations. Furthermore, the surge in pesticide and chemical-related poisoning incidents in agriculture and industrial settings has pushed healthcare providers and regulatory bodies to prioritize the stockpiling and distribution of essential antidotes. As the global landscape of public health crises expands, antidote development continues to evolve to address the increasing complexities of poisoning cases.

How Are Regulations and Safety Protocols Shaping Market Dynamics? The antidote market operates within a highly regulated framework, with government agencies and healthcare organizations imposing strict safety and efficacy requirements. The approval process for antidotes is rigorous, requiring extensive clinical trials and real-world testing to ensure effectiveness in emergency scenarios. The role of regulatory bodies such as the FDA, EMA, and WHO has become pivotal in streamlining approvals for life-saving antidotes, ensuring their availability in hospitals, pharmacies, and emergency response units. Additionally, the global trend toward reducing mortality rates from toxic exposure has led to increasing investments in national stockpile programs. Many governments and international health organizations have prioritized antidote production and distribution as a critical component of public health policy, ensuring rapid response to poisoning incidents and biohazard emergencies. The market is also witnessing a shift towards prefilled auto-injectors and intranasal delivery mechanisms, which improve accessibility and ease of administration in time-sensitive cases.

What Are the Cutting-Edge Innovations Transforming Antidote Efficacy? Technological advancements in pharmaceuticals and biomedical research are revolutionizing antidote formulations, making them more effective, faster-acting, and easier to administer. Innovations such as monoclonal antibody-based antidotes and targeted enzyme inhibitors are improving the specificity of treatment for certain toxic exposures. In parallel, the integration of nanotechnology in drug delivery is enhancing the bioavailability of antidotes, allowing for sustained release and more precise targeting of toxins within the body. Additionally, AI-driven drug discovery is accelerating the identification of novel antidote compounds by analyzing vast chemical databases to match toxicological profiles with potential counteragents. The adoption of point-of-care antidote solutions, such as single-dose auto-injectors for opioid overdoses and cyanide poisoning, is reducing dependency on hospital-based treatments and facilitating immediate intervention in critical scenarios. With these cutting-edge developments, antidote treatment is becoming more patient-centric, with a strong emphasis on portability and rapid administration.

What Are the Key Growth Drivers Fueling Market Expansion? The growth in the global antidotes market is driven by several factors, including increasing incidences of drug overdoses, industrial chemical exposures, and the rising global focus on emergency preparedness. The growing awareness among healthcare professionals and the general public about the importance of timely intervention has led to an increase in antidote stockpiling in hospitals, ambulances, and even households. Additionally, the expanding pharmaceutical industry is fostering the development of novel antidotal therapies, including antidotes for snakebites, heavy metal poisoning, and bioterrorism-related toxic agents. The heightened demand for pre-hospital emergency care, along with the development of portable antidote formulations, is further propelling market growth. Furthermore, the rise in government funding for toxicology research, coupled with strategic partnerships between biotech firms and public health institutions, is ensuring a steady pipeline of advanced antidote solutions. These collective market drivers are shaping the future of antidote accessibility and efficiency, catering to an ever-evolving landscape of toxicological threats.

SCOPE OF STUDY:

The report analyzes the Antidotes market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Chemical Antidote, Pharmacological Antidote, Physical Antidote); Administration Route (Injectable Route, Oral Route, Other Administration Routes); End-Use (Hospitals End-Use, Specialty Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • Acrotech Biopharma, Inc.
  • American Regent, Inc.
  • Baxter International, Inc.
  • Cumberland Pharmaceuticals, Inc.
  • Emergent BioSolutions, Inc.
  • Global Calcium Private Limited
  • Heyl Chemisch-pharmazeutische Fabrik GmbH & Company KG
  • Indivior Plc
  • Padagis US, LLC
  • Pfizer, Inc.
  • ZIMHI
  • Zydus Pharmaceuticals (USA) Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Antidotes - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Incidence of Drug Overdoses Driving Demand for Effective Antidotes
    • Rising Adoption of Specific Antidotes for Targeted Poisoning Cases
    • Growth in Availability of Stockpiled Emergency Antidotes for Public Health Preparedness
    • Expansion of Biologic and Monoclonal Antibody-Based Antidotes
    • Advancements in AI-Driven Drug Discovery for Novel Antidote Development
    • Increasing Strategic Partnerships for Global Distribution of Critical Antidotes
    • Growing Demand for Cost-Effective and Rapid-Acting Antidote Solutions
    • Expansion of Clinical Research in Broad-Spectrum Antidotes
    • Rising Investments in Nanotechnology-Based Antidote Delivery Systems
    • Surge in Awareness and Training Programs for Poison Control and Emergency Response
    • Emerging Innovations in Next-Generation Toxin Neutralization Strategies
    • Increasing Role of Gene Therapy and CRISPR in Developing Advanced Antidote Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Antidotes Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Antidotes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Antidotes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Antidotes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Chemical Antidote by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Chemical Antidote by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Chemical Antidote by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Pharmacological Antidote by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Pharmacological Antidote by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Pharmacological Antidote by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Physical Antidote by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Physical Antidote by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Physical Antidote by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Injectable Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Injectable Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Injectable Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Oral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Specialty Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Antidotes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Antidotes by Type - Percentage Breakdown of Value Sales for Chemical Antidote, Pharmacological Antidote and Physical Antidote for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Antidotes by Administration Route - Percentage Breakdown of Value Sales for Injectable Route, Oral Route and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Antidotes by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Antidotes by Type - Percentage Breakdown of Value Sales for Chemical Antidote, Pharmacological Antidote and Physical Antidote for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Antidotes by Administration Route - Percentage Breakdown of Value Sales for Injectable Route, Oral Route and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Antidotes by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Antidotes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Antidotes by Type - Percentage Breakdown of Value Sales for Chemical Antidote, Pharmacological Antidote and Physical Antidote for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Antidotes by Administration Route - Percentage Breakdown of Value Sales for Injectable Route, Oral Route and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Antidotes by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Antidotes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Antidotes by Type - Percentage Breakdown of Value Sales for Chemical Antidote, Pharmacological Antidote and Physical Antidote for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Antidotes by Administration Route - Percentage Breakdown of Value Sales for Injectable Route, Oral Route and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Antidotes by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Antidotes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Antidotes by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Antidotes by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Antidotes by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Antidotes by Type - Percentage Breakdown of Value Sales for Chemical Antidote, Pharmacological Antidote and Physical Antidote for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Antidotes by Administration Route - Percentage Breakdown of Value Sales for Injectable Route, Oral Route and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Antidotes by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Antidotes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Antidotes by Type - Percentage Breakdown of Value Sales for Chemical Antidote, Pharmacological Antidote and Physical Antidote for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Antidotes by Administration Route - Percentage Breakdown of Value Sales for Injectable Route, Oral Route and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Antidotes by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Antidotes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Antidotes by Type - Percentage Breakdown of Value Sales for Chemical Antidote, Pharmacological Antidote and Physical Antidote for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Antidotes by Administration Route - Percentage Breakdown of Value Sales for Injectable Route, Oral Route and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Antidotes by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Antidotes by Type - Percentage Breakdown of Value Sales for Chemical Antidote, Pharmacological Antidote and Physical Antidote for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Antidotes by Administration Route - Percentage Breakdown of Value Sales for Injectable Route, Oral Route and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Antidotes by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Antidotes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Antidotes by Type - Percentage Breakdown of Value Sales for Chemical Antidote, Pharmacological Antidote and Physical Antidote for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Antidotes by Administration Route - Percentage Breakdown of Value Sales for Injectable Route, Oral Route and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Antidotes by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Antidotes by Type - Percentage Breakdown of Value Sales for Chemical Antidote, Pharmacological Antidote and Physical Antidote for the Years 2015, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Antidotes by Administration Route - Percentage Breakdown of Value Sales for Injectable Route, Oral Route and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Antidotes by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Antidotes by Type - Percentage Breakdown of Value Sales for Chemical Antidote, Pharmacological Antidote and Physical Antidote for the Years 2015, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Antidotes by Administration Route - Percentage Breakdown of Value Sales for Injectable Route, Oral Route and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Antidotes by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Antidotes by Type - Percentage Breakdown of Value Sales for Chemical Antidote, Pharmacological Antidote and Physical Antidote for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Antidotes by Administration Route - Percentage Breakdown of Value Sales for Injectable Route, Oral Route and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Antidotes by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Antidotes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Antidotes by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Antidotes by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Antidotes by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Antidotes by Type - Percentage Breakdown of Value Sales for Chemical Antidote, Pharmacological Antidote and Physical Antidote for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Antidotes by Administration Route - Percentage Breakdown of Value Sales for Injectable Route, Oral Route and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Antidotes by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Antidotes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Antidotes by Type - Percentage Breakdown of Value Sales for Chemical Antidote, Pharmacological Antidote and Physical Antidote for the Years 2015, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Antidotes by Administration Route - Percentage Breakdown of Value Sales for Injectable Route, Oral Route and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Antidotes by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Antidotes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Antidotes by Type - Percentage Breakdown of Value Sales for Chemical Antidote, Pharmacological Antidote and Physical Antidote for the Years 2015, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Antidotes by Administration Route - Percentage Breakdown of Value Sales for Injectable Route, Oral Route and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Antidotes by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Antidotes by Type - Percentage Breakdown of Value Sales for Chemical Antidote, Pharmacological Antidote and Physical Antidote for the Years 2015, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Antidotes by Administration Route - Percentage Breakdown of Value Sales for Injectable Route, Oral Route and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Antidotes by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Antidotes by Type - Percentage Breakdown of Value Sales for Chemical Antidote, Pharmacological Antidote and Physical Antidote for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Antidotes by Administration Route - Percentage Breakdown of Value Sales for Injectable Route, Oral Route and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Antidotes by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Antidotes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Antidotes by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Antidotes by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Antidotes by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Antidotes by Type - Percentage Breakdown of Value Sales for Chemical Antidote, Pharmacological Antidote and Physical Antidote for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Antidotes by Administration Route - Percentage Breakdown of Value Sales for Injectable Route, Oral Route and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Antidotes by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Antidotes by Type - Percentage Breakdown of Value Sales for Chemical Antidote, Pharmacological Antidote and Physical Antidote for the Years 2015, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Antidotes by Administration Route - Percentage Breakdown of Value Sales for Injectable Route, Oral Route and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Antidotes by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Antidotes by Type - Percentage Breakdown of Value Sales for Chemical Antidote, Pharmacological Antidote and Physical Antidote for the Years 2015, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Antidotes by Administration Route - Percentage Breakdown of Value Sales for Injectable Route, Oral Route and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Antidotes by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Antidotes by Type - Percentage Breakdown of Value Sales for Chemical Antidote, Pharmacological Antidote and Physical Antidote for the Years 2015, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Antidotes by Administration Route - Percentage Breakdown of Value Sales for Injectable Route, Oral Route and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Antidotes by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Antidotes by Type - Percentage Breakdown of Value Sales for Chemical Antidote, Pharmacological Antidote and Physical Antidote for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Antidotes by Administration Route - Percentage Breakdown of Value Sales for Injectable Route, Oral Route and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Antidotes by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Antidotes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Antidotes by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Antidotes by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Antidotes by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Antidotes by Type - Percentage Breakdown of Value Sales for Chemical Antidote, Pharmacological Antidote and Physical Antidote for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Antidotes by Administration Route - Percentage Breakdown of Value Sales for Injectable Route, Oral Route and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Antidotes by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Antidotes by Type - Percentage Breakdown of Value Sales for Chemical Antidote, Pharmacological Antidote and Physical Antidote for the Years 2015, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Antidotes by Administration Route - Percentage Breakdown of Value Sales for Injectable Route, Oral Route and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Antidotes by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Antidotes by Type - Percentage Breakdown of Value Sales for Chemical Antidote, Pharmacological Antidote and Physical Antidote for the Years 2015, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Antidotes by Administration Route - Percentage Breakdown of Value Sales for Injectable Route, Oral Route and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Antidotes by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Antidotes by Type - Percentage Breakdown of Value Sales for Chemical Antidote, Pharmacological Antidote and Physical Antidote for the Years 2015, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Antidotes by Administration Route - Percentage Breakdown of Value Sales for Injectable Route, Oral Route and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Antidotes by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Antidotes by Type - Percentage Breakdown of Value Sales for Chemical Antidote, Pharmacological Antidote and Physical Antidote for the Years 2015, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Antidotes by Administration Route - Percentage Breakdown of Value Sales for Injectable Route, Oral Route and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Antidotes by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Antidotes by Type - Percentage Breakdown of Value Sales for Chemical Antidote, Pharmacological Antidote and Physical Antidote for the Years 2015, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Antidotes by Administration Route - Percentage Breakdown of Value Sales for Injectable Route, Oral Route and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Antidotes by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Antidotes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Antidotes by Type - Chemical Antidote, Pharmacological Antidote and Physical Antidote Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Antidotes by Type - Percentage Breakdown of Value Sales for Chemical Antidote, Pharmacological Antidote and Physical Antidote for the Years 2015, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Antidotes by Administration Route - Injectable Route, Oral Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Antidotes by Administration Route - Percentage Breakdown of Value Sales for Injectable Route, Oral Route and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Antidotes by End-Use - Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Antidotes by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION